The study is a phase II single-centered, single group, prospective clinical trial to evaluate
the safety of HMA-CD20 doses among stable patients with class III/IV according to the NYHA
classification with HFrEF receiving standard of care therapy. The index qualifying HFrEF must
have EF < 40% based on echocardiographic or cardiac MRI techniques, heart failure class
III/IV according to the NYHA classification,aged 40-60 years, being diagnosed less than 12
months before enrollment of study, following the standard heart failure treatment regimen.
Phase:
Phase 2
Details
Lead Sponsor:
Instituto de Cardiología y Medicina Vascular Hospital Zambrano-Hellion Tec Salud